FINWIRES · TerminalLIVE
FINWIRES

$CAPR

15 stories mentioning CAPRUpdated 11d ago

Every FINWIRES story that references CAPR, newest first.

What are analysts saying about CAPR?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on CAPR?

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5%.The iShares Biotechnology ETF (IBB) increased 0.7%.In corporate news, Capricor Therapeutics (CAPR) shares rose 1.5% after Piper Sandler upgraded the company's stock to overweight from neutral and adjusted its price target to $25 from $2.Novartis (NVS) shares jumped over 6% after it said Tuesday that phase 3 trials of remibrutinib showed significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis. The trials met their primary endpoints and showed that remibrutinib was superior to teriflunomide on all key secondary measures.Medtronic (MDT) shares gained 1.4%. The company lifted its full-year outlook on Tuesday as it reported better-than-expected fiscal Q1 results.Alumis (ALMS) shares fell 56% after the company said a phase 2 trial of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.

$ALMS$CAPR$MDT$NVS
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5%.The iShares Biotechnology ETF (IBB) increased 0.7%.In corporate news, Capricor Therapeutics (CAPR) shares rose 3.8% after Piper Sandler upgraded the company's stock to overweight from neutral and adjusted its price target to $25 from $2.

$CAPR
Wire

Capricor Therapeutics Shares Rise After Piper Sandler Upgrade

Capricor Therapeutics (CAPR) shares were up 4.5% in Tuesday trading after Piper Sandler upgraded the company's stock to overweight from neutral and adjusted its price target to $25 from $2.Trading volume stood at about 4.1 million shares, compared with a daily average of about 6 million.Price: $10.36, Change: $+0.45, Percent Change: +4.54%

$CAPR
Research

Piper Sandler Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $25 From $2

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $31.78, according to analysts polled by FactSet.

$CAPR
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each fractionally lower.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Personalis (PSNL) shares fell past 7% after Craig-Hallum downgraded the stock to hold from buy.Biomea Fusion (BMEA) shares surged past 18% after the company said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, news outlets reported Monday, citing a company statement. Lilly shares were down 0.5%.Capricor Therapeutics (CAPR) said Monday the US Food and Drug Administration has extended the target action date for its biologics license application for deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22. Capricor shares jumped past 8%.Regenxbio (RGNX) shares fell more than 23% after the company said it does not plan to resubmit the biologics license application for its investigational gene therapy RGX-121 for Hunter syndrome in the near term following a US Food and Drug Administration clinical hold.

$BMEA$CAPR$LLY$PSNL$RGNX
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Eli Lilly (LLY) has launched its Foundayo weight-loss pill in the UK, making Britain the first European country where the oral treatment is available, news outlets reported Monday, citing a company statement. Lilly shares were down 0.8%.Capricor Therapeutics (CAPR) said Monday the US Food and Drug Administration has extended the target action date for its biologics license application for deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22. Capricor shares jumped past 6%.Regenxbio (RGNX) shares fell more than 23% after the company said it does not plan to resubmit the biologics license application for its investigational gene therapy RGX-121 for Hunter syndrome in the near term following a US Food and Drug Administration clinical hold.

$CAPR$LLY$RGNX
Wire

Capricor Therapeutics Says FDA Target Action Date for Deramiocel Extended by Three Months

Capricor Therapeutics (CAPR) said Monday the Food and Drug Administration has extended the target action date on its biologics license application for Deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22.The extension is for the FDA's review of a major amendment to the application, which the company submitted to include additional data from a phase 3 study, Capricor said.Shares of Capricor Therapeutics were more than 3% higher in Monday trading.Price: $6.54, Change: $+0.25, Percent Change: +3.97%

$CAPR
Sectors

Sector Update: Healthcare Stocks Flat to Lower Pre-Bell Friday

Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.2%.Heartflow (HTFL) stock was up nearly 24% after the company posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.Valneva (VALN) shares were up nearly 26% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer stock was 0.1% lower premarket.Capricor Therapeutics (CAPR) shares were up more than 85% after the company said the US Food and Drug Administration is willing to review an amendment to its biologics license application for deramiocel, potentially shifting the drug's focus to upper-limb skeletal muscle function in Duchenne muscular dystrophy.

$CAPR$HTFL$IBB$PFE$VALN$XLV
Research

Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $28 From $3.50

Capricor Therapeutics (CAPR) has an average rating of hold and mean price target of $26.12, according to analysts polled by FactSet.

$CAPR
Research

Oppenheimer Downgrades Capricor Therapeutics to Perform From Outperform, Price Target is $54

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $29.35, according to analysts polled by FactSet.Price: $3.00, Change: $-3.57, Percent Change: -54.34%

$CAPR
Research

Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral From Overweight, Adjusts PT to $3.50 From $62

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $29.35, according to analysts polled by FactSet.

$CAPR
Research

HC Wainwright Downgrades Capricor Therapeutics to Neutral From Buy

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $29.35, according to analysts polled by FactSet.

$CAPR
Wire

Capricor Therapeutics Shares Fall After B. Riley, Roth Capital Downgrades

Capricor Therapeutics (CAPR) shares fell about 12% on Tuesday after B. Riley and Roth Capital downgraded the stock to neutral from buy.B. Riley cut its price target to $10 per share from $63, while Roth Capital lowered its target to $7 per share from $38.Trading volume stood at over 11.5 million shares, compared with a daily average of more than 1.8 million.Price: $6.18, Change: $-0.81, Percent Change: -11.61%

$CAPR
Research

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63

Capricor Therapeutics (CAPR) has an average rating of buy and mean price target of $45.20, according to analysts polled by FactSet.

$CAPR
Research

Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38

Capricor Therapeutics (CAPR) has an average rating of Buy and mean price target of $45.20, according to analysts polled by FactSet.

$CAPR

Track with the FINWIRES app suite

FolioX
FolioX
Track CAPR in your portfolio
WheelAI
WheelAI
Analyze CAPR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CAPR